Precision radiation aims to spare kidneys in cancer fight

NCT ID NCT07402109

First seen Feb 11, 2026 · Last updated Jun 23, 2026 · Updated 24 times

Summary

This study tests a new way to deliver radiotherapy for kidney cancer that uses advanced imaging to target the tumor more precisely. The goal is to reduce radiation damage to healthy kidney tissue. About 40 adults with non-spreading kidney cancer will receive this treatment. Researchers will measure how much healthy kidney is spared and whether the tumor is still fully covered.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Erasmus MC

    RECRUITING

    Rotterdam, South Holland, 3000CA, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

radiation therapy

What this could lead to

If successful, this approach could allow more precise, kidney-sparing radiotherapy for kidney cancer patients, reducing side effects.

What could go wrong

This is a small, early-phase study with only 40 participants. The technique may not improve outcomes or could cause additional radiation exposure from extra imaging.

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.